BioXcel Therapeutics

Contributing Author

Recent Articles by BioXcel Therapeutics

Apr-01	BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting BTAI -8.96% GlobeNewswire
Mar-27	BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI Approval in Outpatient Setting BTAI -8.03% GlobeNewswire
Mar-11	BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering BTAI GlobeNewswire
Mar-10	BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering BTAI -10.40% GlobeNewswire
Mar-05	BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal BTAI GlobeNewswire
Feb-19	BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia BTAI GlobeNewswire
Feb-12	BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI in the At-Home Setting BTAI GlobeNewswire
Jan-20	BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI Label Expansion in the At-Home Setting BTAI GlobeNewswire
Jan-12	BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI in the At-Home Setting BTAI GlobeNewswire
Jan-07	BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI BTAI +17.24% GlobeNewswire
Dec-03	Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions BTAI GlobeNewswire
Nov-12	BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease BTAI -15.35% GlobeNewswire
Oct-14	BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes BTAI GlobeNewswire
Oct-13	BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation BTAI GlobeNewswire
Sep-18	BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements BTAI GlobeNewswire
Sep-10	BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia BTAI GlobeNewswire
Sep-04	BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference BTAI GlobeNewswire
Aug-27	UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI BTAI -24.43% GlobeNewswire
Aug-27	BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI BTAI -24.43% GlobeNewswire
Aug-26	BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025 BTAI GlobeNewswire
Aug-19	BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia BTAI -13.23% GlobeNewswire
Aug-18	BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia BTAI GlobeNewswire
Aug-13	BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. "HCW@Home" Series BTAI -17.65% GlobeNewswire
Aug-12	BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates BTAI +6.25% GlobeNewswire
Aug-11	BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference BTAI +58.42% GlobeNewswire
Aug-06	BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies BTAI +11.78% GlobeNewswire
Aug-01	BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia BTAI GlobeNewswire
Jul-21	BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI BTAI GlobeNewswire
Jul-01	BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia BTAI +8.84% GlobeNewswire
May-27	BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia BTAI GlobeNewswire
May-27	BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement BTAI GlobeNewswire
May-12	BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update BTAI GlobeNewswire

BioXcel Therapeutics

Recent Articles by BioXcel Therapeutics

Upgrade your Finviz experience